Kinevant science's drug science namilumab在治疗沙质病的第二阶段研究失败了。 Kinevant Sciences' drug namilumab fails in Phase 2 study for treating sarcoidosis.

Kinevant Sciences 的 namilumab 治疗慢性活动性肺结节病的 2 期研究未显示任何治疗益处。 Kinevant Sciences' Phase 2 study of namilumab for chronic active pulmonary sarcoidosis failed to show any treatment benefits. RESOLVE-Lung研究旨在评估药物的功效和安全性,但没有达到其主要目的或次要目标。 The RESOLVE-Lung study, which aimed to assess the drug's efficacy and safety, did not meet its primary endpoint or secondary goals. 尽管安全性与早期研究一致，但 Kinevant 将停止进一步开发用于治疗结节病的 namilumab。 Despite a safety profile consistent with earlier studies, Kinevant will halt further development of namilumab for treating sarcoidosis.